RxDoctor Payments Data

Jeffrey Boesch, MD

Internal Medicine · Chesterfield, MONPI 1972566024

Payments from drug & device makers

$9,407in general payments, 2019–2025

Across 46 payments — averaging $204.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$8K
  • Camber Spine Technologies LLC$278
  • AstraZeneca$272
  • GSK$260
  • Boehringer Ingelheim$139
  • Amgen$138
  • plus $797 from 12 others

What the payments were for

  • Consulting fees$2252%
  • Speaking & faculty fees$6,30067%
  • Travel & lodging$1,28514%
  • Food & beverage$1,48116%
  • Education$1161%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,407 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$88,701
Medicare patients
459
Services billed
1,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$345,915
JardianceEmpagliflozin89$117,029
JanuviaSitagliptin Phosphate106$103,101
XareltoRivaroxaban94$80,147
OzempicSemaglutide52$59,698
TradjentaLinagliptin78$49,776
MyrbetriqMirabegron62$38,162
EntrestoSacubitril/Valsartan45$34,351
FarxigaDapagliflozin Propanediol44$31,397
ArexvyRsvpref3 Antigen/As01e/Pf115$30,318
CreonLipase/Protease/Amylase15$27,866
Janumet XrSitagliptin Phos/Metformin Hcl19$23,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,987
RexultiBrexpiprazole21$16,417
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$15,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$73$352,496460 claims
Boehringer IngelheimJardiance, Tradjenta$139$166,805167 claims
MerckJanuvia, Janumet Xr$17$126,393125 claims
Johnson & JohnsonXarelto$20$80,14794 claims
GSKArexvy, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta$260$74,914184 claims
Novo NordiskOzempic$23$59,69852 claims
AstraZenecaFarxiga$272$31,39744 claims
Lilly USA, LLCMounjaro$97$13,54912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →